Publicidad
Contribución especial 04 de mayo de 2012

Alteraciones en la biodistribución de los radiofármacos causadas por interacciones medicamentosas

Referenciar Imprimir Descargar PDF

Referencias

  1. Hladik WB 3rd, Nigg KK, Rhodes BA. Drug-induced changes in the biologic distribution of radiopharmaceuticals. Semin Nucl Med 1982;12:184-218.
  2. Sampson CB. Patient medication and nuclear medicine tests: A pharmacist’s viewpoint. Nuc Med Commun 1998;19:519-20.
  3. Owunwanne A, Shihab-Eldeen A, Yacoub T, Ziada G. The use of radiopharmaceuticals as an effective toxicologic technique for studying nephrotoxicity of drugs: cyclosporine-A. Hum Exp Toxicol 1998;17:613-9.
  4. Hommeyer SH, Varney DM, Eary JF. Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy. J Nucl Med 1992;33:748-50.
  5. Murphy KJ, Line BR, Malfetano J. Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. Can Assoc Radiol J 1997;48:199-202.
  6. Pecherstorfer M, Schilling T, Janisch S, Woloszczuk W, Baumgartner G, Ziegler R, et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993;34:1039-44.
  7. Park CH, Kim HS, Shin HY, Kim HC. Hepatic uptake of Tc-99m MDP on bone scintigraphy from intravenous iron therapy (Blutal). Clin Nucl Med 1997;22:762-4.
  8. Eshima M, Shiozaki H, Ishino Y, Nakata H. Diffuse liver uptake of Tc-99m phosphate compound associated with intravenous injection of iron colloid solution. Clin Nucl Med 1993;18:348-9.
  9. Choy D, Murray IP, Hoschl R. The effect of iron on the biodistribution of bone scanning agents in humans. Radiology 1981;140:197-202.
  10. Cronhjort M, Saaf M, Sjoberg HE, Schnell PO, Jacobsson H. Influence of the phosphate balance on the activity distribution of 99mTc-hydroxy-methylene diphosphonate. Experimental studies in the mouse. Acta Radiol 1998;39:427-33.
  11. Lutrin Cl, Mc Dougall IR, Goris MI. Intense concentration of Tc-99m pyrophosphate in the kidneys of children treated with chemotherapeutic drugs for malignant disease. Radiology 1978;128:165-7.
  12. Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. Experience with community-based amphotericin B infusion therapy. Pharmacotherapy 2005;25:690-7.
  13. Chen WL, Perng MY, Hwei DZ, Yu MD. Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction. J Nucl Biol Med 1994;38(Suppl 1):132-4.
  14. McAfee JG, Singh A, Roskoopf M, Ritter C, Lyons B, Schoonmaker JF. Experimental drug-induced changes in renal function and biodistribution of 99mTc-MDP. Invest Radiol 1983;18:470-8.
  15. Zimmer AM, Pavel DG. Experimental investigations of the possible cause of liver appearance during bone scanning. Radiology 1978;126:813-6.
  16. Palmer AM, Watt I, Dieppe PA. Soft-tissue localization of 99mTc-hydroxymethylene diphosphonate due to interaction with calcium. Clin Radiol 1992;45:326-30.
  17. Schmitt GH, Holmes RA, Isitman AT, Hensley GT, Lewis JD. A proposed mechanism for 99mTc-labeled polyphosphate and diphosphonate uptake by human breast tissue. Radiology 1974;112:733-5.
  18. Hugues FC, Gourlot C, Le Jeunne C. Drug-induced ginecomastia. Ann Med Interne 2000;151:10-7.
  19. Scott S, Alazraki N, Manaster B. Failure of bone scanning to detect fractures in a woman on chronic steroid therapy. Skeletal Radiol 1984;12:204-7.
  20. Van Renterghem D, De Reuck J, Schelstraete K, Elinck W, Van Der Straeten M. Epsilon amino caproic acid myopathy: additional features. Clin Neurol Neurosurg 1984;86:153-7.
  21. Murphy KJ, Line BR, Malfetano J. Etidronate therapy decreases the sensitivity of bone scanning with methylene diphosphonate labelled with technetium-99m. Can Assoc Radiol J 1997;48:199-202.
  22. Hiltz A, Iles SE. Abnormal distribution of Tc-99m iminodiphosphonate due to iron dextran therapy. Clin Nucl Med 1990;15:818-20.
  23. Carr EA Jr, Carroll M, Montes M. Effect of vitamin D3, other drugs altering serum calcium or phosphorus concentrations, and desoxycorticosterone on the distribution of Tc-99m pyrophosphate between target and nontarget tissues. J Nucl Med 1981;22:526-34.
  24. Mathov I, Plotkin LI, Sgarlata CL, Leoni J, Bellido T. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 2001;16:2050-6.
  25. Salgia R, Demetri GD, Kaplan WD. Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. Cancer 1994;74:1887-90.
  26. Flynn BM, Treves ST. Diffuse hepatic uptake of technetium-99m methylene diphosphonate in a patient receiving high dose methotrexate. J Nucl Med 1987;28:532-4.
  27. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975;16:744-55.
  28. Eisenberg B, Owens D, Stewart DL, Williamson MR. PYP Maalox localization in liver and spleen. Clin Nucl Med 1989;14:636.
  29. Chacko AK, Gordon DH, Bennett JM, O'Mara RE, Wilson GA. Myocardial imaging with Tc-99m pyrophosphate in patients on adriamycin treatment for neoplasia. J Nucl Med 1977;18:680-3.
  30. Fujita N, Hiroe M, Suzuki Y, Sato H, Inoue Y, Sekiguchi M, et al. A case with cardiac sarcoidosis. Significance of the effect of steroids on the reversion of advanced atrioventricular block and myocardial scintigraphic abnormalities. Heart Vessels Suppl 1990;5:16-8.
  31. Schneider RM, Hayslett JP, Downing SE, Berger HJ, Donabedian RK, Zaret BL Effect of methylprednisolone upon technetium-99m pyrophosphate assessment myocardial necrosis in the canine countershock model. Circulation 1977;56:1029-34.
  32. Candell J, Castell J, Jurado J, López de Sá E, Nuño de la Rosa J, Ortigosa F et al. Guías de actuación clínica de la Sociedad Española de Cardiología. Cardiología nuclear: bases técnicas y aplicaciones clínicas. Rev Esp Cardiol 1999;52:957-989.
  33. Taillefer R, Ahlberg AW, Masood Y, White CM, Lamargese I, Mather JF et al. Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging. J Am Coll Cardiol 2003;42:1475-83.
  34. Narahara KA, Thomson CJ, Hazen JF, Brizendine M, Mena I. The effect of beta blockade on single photon emission computed tomographic (SPECT) thallium-201 images in patients with coronary disease. Am Heart J 1989;117:1030-5.
  35. Sharir T, Rabinowitz B, Livschitz S, Moalem I, Baron J, Kaplinsky E, Chouraqui P. Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs. Jam Coll Cardiol 1998;31:1540-6.
  36. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004;9:243-55.
  37. Fung HL. Clinical pharmacology of organic nitrates. Am J Cardiol 1993;72:9C-13C.
  38. Dewitt CR, Waksman JC. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol Rev 2004;23:223-38.
  39. Sarin B, Chugh PK, Kaushal D, Soni NL, Sawroop K, Mondal A et al. Sodium bicarbonate-augmented stress thallium myocardial scintigraphy. Eur J Nucl Med Mol Imaging 2004;31:475-81.
  40. Laine H, Sundell J, Nuutila P, Raitakari OT, Luotolahti M, Rönnemaa T. Insulin induced increase in coronary flow reserve is abolished by dexamethasone in young men with uncomplicated type 1 diabetes. Heart 2004;90:270-6.
  41. Waschek J, Hinkle G, Basmadjian G, Allen EW, Ice R. Effect of cardiac drugs on imaging studies with thallous chloride Tl 201. Am J Hosp Pharm 1981;38:1726-8.
  42. Keenan SM, DeLisle RK, Welsh WJ, Paula S, Ball WJ Jr..Elucidation of the Na+, K+-ATPase digitalis binding site. J Mol Graph Model 2005;23:465-75.
  43. Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys 2001;49:1023-8.
  44. Hesslewood S, Leung E. Drug interactions with radiopharmaceuticals. Eur J Nucl Med 1994;21:348-56.
  45. Gilman AG, Rall TW, Nies AS (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (8th ed). Pergamon Press, New York, NY, 1990.
  46. Nascimento Cardoso V, Roca M, Martín-Comín J. No influence of propanolol, cyclosporine, adriamycin, and nifedipine on the in vitro labelling of erythrocytes. Rev Esp Med Nucl 2002;21:24-7.
  47. Porter WC, Dees SM, Freitas JE, Dworkin HJ. Acid-citrate-dextrose compared with heparin in the preparation of in vivo/in vitro technetium-99m red blood cells. J Nucl Med 1983;24:383-7.
  48. Sampson CB. Adverse reactions and drug interactions with radiopharmaceuticals. Drug Safety 1993;8:280-94.
  49. Lee HB, Wexler JP, Scharf SC, Blaufox MD. Pharmacologic alterations in Tc-99m binding by red blood cells: concise communication. J Nucl Med 1983;24:397-401.
  50. White PM, Mann A, Dawn M, Heller GV. Evaluation of 99mTechnetium red blood cells labelling efficiency in adults receiving chemotherapy and the clinical impact in pediatric oncology patients. J Nucl Med Technol 1998;26:265-8.
  51. Sampson CB. Complications and difficulties in radiolabelling blood cells: a review. Nucl Med Commun 1996;17:648-58.
  52. Tatum JL, Burke TS, Hirsch JI, Miler WW, Fratkin MJ. Pitfall to modified in vivo method of technetium-99m red blood cell labeling: Iodinated contrast media. Clin Nucl Med 1983;8:585-7.
  53. Fang GX, Chan PCK, Cheng IKP. Haematological changes after renal transplantation: differences between cyclosporin-A and azathioprine therapy. Int Urol Nephrol 1990;22:181-7.
  54. Mechanick JI. Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review and discussion of pathogenesis. Mt Sinai J Med 1985;52:667-70.
  55. Stimac D, Milic S, Dintinjana RD, Kovac D, Ristic S. Androgenic/anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002;35:350-2.
  56. Zafrani ES, Pinaudeau Y, Dhumeaux D. Drug-induced vascular lesions of the liver. Arch Intern Med 1983;143:495-502.
  57. Focal nodular hyperplasia associated with the use of a synthetic anabolic androgen. Am J Gastroenterol 1984;79:150-1.
  58. Mettlin C. Studies on the role of oral contraceptive use in the etiology of benign and malignant liver tumors. J Surg Oncol 1981;18:73-85.
  59. Vana J, Murphy G, Aronoff BL, Baker HW. Primary liver tumors and oral contraceptives. Results of a survey. JAMA 1977;238:2154-8.
  60. Bobinet DD, Sevrin R, Zurbriggen MT, Spolter L, Cohen MB. Lung uptake of 99mTc-sulfur colloid in patient exhibiting presence of Al3+ in plasma. J Nucl Med 1974;15:1220-2.
  61. Malmud LS, Charkes ND, Littlefield J, Reilley J, Stern H, Rosenberg R et al. The mode of action alginic acid compound in the reduction of gastroesophageal reflux. J Nucl Med 1979;20:1023-8.
  62. Malmud LS, Fisher RS. The evaluation of gastroesophageal reflux before and after medical therapies. Semin Nucl Med 1981;11:205-15.
  63. Marano AR, Caride VJ, Prokop EK, Troncale FJ, McCallum RW. Effect of sucralfate and an aluminum hydroxide gel on gastric emptying of solids and liquids. Clin Pharmacol Ther 1985;37:629-32.
  64. Kaplan WD, Drum DE, Lokich JJ. The effect of cancer chemotherapeutic agents on the liver-spleen scan. J Nucl Med 1980;21:84-7.
  65. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001;6:162-76.
  66. Lentle BC, Scott JR, Noujaim AA, Jackson FI . Iatrogenic alterations in radionuclide biodistributions. Semin Nucl Med 1979;9:131-43.
  67. Villeneuve JP, Pichette V. Cytochrome P450 and liver diseases. Curr Drug Metab 2004;5:273-82.
  68. Hasan F. Isoflurane hepatotoxicity in a patient with a previous history of halothane-induced hepatitis. Hepatogastroenterology 1998;45:518-22.
  69. Keyes JW Jr, Wilson GA, Quinonest JD. An evaluation of lung uptake of colloid during liver imaging. J Nucl Med 1973;14:687-91.
  70. Beatson N. Atropine and paralytic ileus. Postgrad Med J 1982;58:451-3.
  71. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004;16 (Suppl 2):17-28.
  72. Penagini R, Allocca M, Cantu P, Mangano M, Savojardo D, Carmagnola S. Relationship between motor function of the proximal stomach and transient lower oesophageal sphincter relaxation after morphine. Gut 2004;53:1227-31.
  73. Banzo I. Gammagrafía hepatobiliar: metodología y aplicaciones clínicas. Rev Esp Med Nuclear 1998;17:122-9.
  74. Lorberhoym M, Simon J, Horne T. The role of morphine-augmented cholescintigraphy and real-time ultrasound in detecting gallbladder disease. J Nucl Med Technol 1999;27:294-7.
  75. Pedersen SA, Oster-Jorgensen E, Kraglund K. The effects of morphine on biliary dynamics. A scintigraphic study with 99mTc-HIDA. Scand J Gastroenterol 1987;22:982-6.
  76. Coenegracht JM, Oei TL, van Breda Vriesman PJ. The influence of bilirubin, alcohol and certain drugs on the kinetics of 99mTc-Diethyl IDA (EHIDA) in humans. Eur J Nucl Med 1983;8:140-4.
  77. Shafer RB, Knodell RG, Stanley LN, Elson MK. Acute effects of nicotinic acid on hepatic transport of 99mTc-PIPIDA. Eur J Nucl Med 1983;8:12-4.
  78. Curran TJ, Uzoaru I, Das JB, Ansari G, Raffensperger JG. The effect of cholecystokinin-octapeptide on the hepatobiliary dysfunction caused by total parenteral nutrition. J Pediatr Surg 1995;30:242-6.
  79. Llamas-Elvira JM, Sopena R, Martínez-Paredes M, Jimenez-Hefferman A, González FM, Torres M et al. Muscarinic control of gallbladder dynamics. A study using 99Tcm-HIDA and cholinergic agonists and antagonists. Nucl Med Commun 1990;11:813-7.
  80. Kostrubsky VE, Strom SC, Hanson J, Urda E, Rose K, Burliegh J et al. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 2003;76:220-8.
  81. Wilkinson NW, Gustafson RJ, Frizzi JD. The effect of erythromycin on bile excretion and proximal small bowel motility following divided gastric bypass surgery: a prospective randomized placebo-controlled trial. Obes Surg 2002;12:765-72.
  82. Patel NJ, Zamek-Gliszcynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ et al. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol Pharmacol 2003;64:154-9.
  83. Majd M, Reba RC, Altman RP. Effect of phenobarbital on 99mTc-IDA scintigraphy in the evaluation of neonatal jaundice. Semin Nucl Med 1981;11:194-204.
  84. Owunwanne A, Shihab-Eldeen A, Yacoub T, Ziada G. The use of radiopharmaceuticals as an effective toxicologic technique for studying nephrotoxicity of drugs: cyclosporine-A. Hum Exp Toxicol 1998;17:613-9.
  85. Lora-Michiels M, Anzola K, Amaya G, Solano M. Quantitative and qualitative scintigraphic measurement of renal function in dogs exposed to toxic doses of Gentamicin. Vet Radiol Ultrasound 2001;42:553-61.
  86. Herzog KM, Deutsch E, Deutsch K, Silberstein EB, Sarangarajan R, Cacini W. Synthesis and renal excretion of technetium-99m-labeled organic cations. J Nucl Med 1992;33:2190-5.
  87. Ludwig V, Martin WH, Delbeke D. Calcium channel blockers: a potential cause of false-positive captopril renography. Clin Nucl Med 2003;28:108-12.
  88. Claveau-Tremblay R, Turpin S, De Braekeleer M, Brassard A, Leblond R. False-positive captopril renography in patients taking calcium antagonists. J Nucl Med 1998;39:1621-6.
  89. Gomes ML, de Mattos DM, de Souza Freitas R, Bezerra RJ, Bernardo-Filho M. Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations. Hum Exp Toxicol 2001;20:193-7.
  90. Yee CA, Lee HB, Blaufox MD. Tc-99m DMSA renal uptake: influence of biochemical and physiologic factors. J Nucl Med 1981;22:1054-8.
  91. Green DA, Davies SG. Dimercaptosuccinic acid distribution in renal tubular acidosis. Br J Radiol. 1997;70(840):1291-2.
  92. Acosta Gomez MJ, Llamas Elvira JM, Rodriguez Fernandez A, Gomez Rio M, Lopez Ruiz JM, Muros De Fuentes MA, et al. Diagnosis of renovascular hypertension by pre- and post-captopril renal scintigraphy with 99mTc-DMSA. Rev Esp Med Nucl 2001;20:537-43.
  93. Pelosi E, Masaneo I, Clara R, Valetto MR, Bello M, Zanon C. Technetium-99m labelled macroaggregated albumin arterial catheter perfusion scintigraphy: prediction of gastrointestinal toxicity in hepatic arterial chemotherapy. Eur J Nucl Med 2000;27:668-75.
  94. Basoglu T, Erkan L, Canbaz F, Bernay I, Onen T, Sahin M et al. Transient reverse ventilation-perfusion mismatch in acute pulmonary nitrofurantoin reaction. Ann Nucl Med 1997;11:271-4.
  95. Jankovic DL, Djokic DDj Alteration of the organ uptake of the (99m)Tc-radiopharmaceuticals, (99m)Tc-DPD, (99m)Tc-DMSA, (99m)Tc-tin colloid and (99m)Tc-MAA, induced by the applied cytotoxic drugs methotrexate sodium and cyclophosphamide. Nucl Med Commun 2005;26:415-9.
  96. Sovijarvi AR, Poyhonen L, Kellomaki L, Muittari A. Effects of acute and long-term bronchodilator treatment on regional lung function in asthma assessed with krypton-81m and technetium-99m-labelled macroaggregates. Thorax 1982;37:516-20.
  97. Datz FL, Christian PE, Hutson WR, Moore JG, Morton KA. Physiological and pharmacological interventions in radionuclide imaging of the tubular gastrointestinal tract. Semin Nucl Med 1991;21:140-52.
  98. Wang TS, Fawwaz RA, Esser PD, Johnson PM. Altered body distribution of [99mTc] pertechnetate in iatrogenic hyperaluminemia. J Nucl Med 1978;19:381-3.
  99. Duszynski DO, Jewett TC, Allen JE. Tc 99m Na pertechnetate scanning of the abdomen with particular reference to small bowel pathology. Am J Roentgenol Radium Ther Nucl Med 1971;113:258-62.
  100. Francis MD, Slough CL, Tofe AJ. Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues. Calcif Tissue Res 1976;20:303-11.
  101. Khettery J, Effmann E, Grand RJ, Treves S. Effect of pentagastrin, histalog, glucagon, secretin, and perchlorate on the gastric handling of 99mTc pertechnetate in mice. Radiology 1976;120:629-31.
  102. Sfakianakis GN, Conway JJ. Detection of ectopic gastric mucosa in Meckel’s diverticulum and other aberrations by scintigraphy: I. Pathophysiology and 10 year clinical experience. J Nucl Med 1981;22:647-54.
  103. Yeker D. Radionuclide imaging of Meckel’s diverticulum: cimetidine versus pentagastrine plus glucagon. Eur J Nucl Med 1984;9:316-9.
  104. Castronuovo JJ, Chervu LR, Milstein DM. Altered distribution of technetium-99m sodium pertechnetate associated with antimicrobial therapy. Clin Nucl Med 1985;10:868-71.
  105. Specht HD, Belsey R, Hanada J. Aluminemic disturbance of technetium-99m DTPA renal function measurement. J Nucl Med 1987;28:383-6.
  106. Inou Y, Momose T, Machida K, Honda N, Mamiya T, Takahashy T. A new method for monitoring the cerebrovascular response to acetazolamide using 99mTc-DTPA-HSA. Radiat Med 1992;10:45-7.
  107. McAfee JG, Thomas FD, Subramanian G, Roskopf M, Hellwing B. Evaluation of cyclosporine nephrotoxicity in rats with various renal radioactive agents. J Nucl Med 1988;29:1577-81.
  108. Gomes ML, de Mattos DM, de Souza Freitas R, Bezerra RJ, Bernardo-Filho M. Study of the toxicological effect of mitomycin C in mice: alteration on the biodistribution of radiopharmaceuticals used for renal evaluations. Hum Exp Toxicol 2001;20:193-7.
  109. Dirlik A, Erinc R, Ozcan Z, Atasever A, Bacakoglu F, Nalbantgil S et al. Technetium-99m-DTPA aerosol scintigraphy in amiodarone induced pulmonary toxicity in comparison with Ga-67 scintigraphy. Ann Nucl Med 2002;16:477-81.
  110. Fischer M, Vetter W, Winterg B, Zidek W, Vetter H. Adrenal scintigraphy in primary aldosteronism. Spironolactone as a cause of incorrect classification between adenoma and hyperplasia. Eur J Nucl Med 1982;7:222-4.
  111. Mila Lopez M, Castell-Conesa J, Pifarre Montaner P, Lorenzo Bosquet C, Garcia-Burillo A, Porta Biosca F. Adrenal cortex scintigraphy with and without dexamethasone suppression in the study of primary aldosteronism. Rev Esp Med Nucl 2004;23:324-9.
  112. Shapiro B, Grekin R, Gross MD, Freitas JE. Interference by spironolactone on adrenocortical scintigraphy and other pitfalls in the location of adrenal abnormalities in primary aldosteronism. Clin Nucl Med 1994;19:441-5.
  113. Gross MD, Valk TW, Swanson DP, Thrall JH, Grekin RJ, Beirewaltes WH. The role of parmacologic manipulation in adrenal cortical scintigraphy. Semin Nucl Med 1981;11:128-48.
  114. Hoefnagel CA, Schornagel J, Valdes Olmos RA. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med 1991;35:308-12.
  115. Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 1994;21:545-59.
  116. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513-21.
  117. Apeldoom L, Voerman HJ, Hoefnagel CA. Interference of MIBG uptake by medication: a case report. Neth J Med 1995;46:239-43.
  118. Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30:481-9.
  119. C Sampol Bas; C Peña Viloria. Captación de 123I-MIBG en un hemangioma hepático en el estudio gammagráfico de una lesión suprarrenal. Rev Esp Med Nucl 2005;24:191-4.
  120. Chilton HM, Witcofski RL, Watson NE Jr, Heise CM. Alteration of gallium-67 distribution in tumor bearing mice following treatment with methotrexate: concise comunication. J Nucl Med 1981;22:1064-8.
  121. Lentle BC, Starreveld E, Catz Z, Penney H, Turner AR. Abnormal biodistribution of radiogallium in persons treated with phenytoin. J Can Assoc Radiol 1983;34:114-5.
  122. Khan AS, Dadparvar S, Brown SJ, Slizofski WJ, Roman R, Krishna L, Meihoffer M. The role of gallium-67-citrate in the detection of phenytoin-induced pneumonitis. J Nucl Med 1994;35:471-3.
  123. Moinuddin M. Radionuclide scanning in the detection of drug-induced lung disorders. J Thorac Imaging 1991;6:62-7.
  124. Fukuchi K, Sasaki H, Yokoya T, Noguchi T, Goto Y, Hayashida K et al. Ga-67 citrate and F-18 FDG uptake in spironolactone-induced gynecomastia. Clin Nucl Med 2005;30:105-6.
  125. Kumar M, Abdel-Dayem HM, Naddaf S. Ga-67 uptake by the male breast under digitalis influence (Abstract). Clin Nucl Med 1998;23:779.
  126. Baker DL, Manno CS. Rapid excretion of gallium-67 isotope in an iron-overloaded receiving high–dose intravenous deferoxamine. Am J Hematol 1988;29:230-2.
  127. Loesberg AC, Martin WB. Altered biodistribution of Ga-67 citrate in an iron-overloaded with sickle cell disease. Clin Nucl Med 1994;19:157-9.
  128. Gorenberg M, Groshar D, Even Sapir E. Ga-67 uptake unsuppressed by leukopenia and intense antibiotic therapy. Clin Nucl Med 1992;17:97-8.
  129. Wood BC, Sharman JN, Germann DR, Wood WG, Crouch TT. Gallium citrate Ga 67 imaging in noninfectious interstitial nephritis. Arch Intern Med 1978;138:1665-6.
  130. Handa SP. Drug-induced acute interstitial nephritis: report of 10 cases. CMAJ 1986;135:1278-81.
  131. Hatfield MK, Martin WB, Ryan JW, Vokes EE, Vogelzang NJ. Cardiac gallium uptake in doxorubicin-induced cardiotoxicity. Clin Nucl Med 1986;11:756-7.
  132. Waxman AD, Beldon JR, Richli W, Tanasescu DE, Siemsen JK. Steroid-induced suppression of gallium uptake in tumors of the central nervous system: concise communication. Nucl Med 1978;19:480-2.
  133. Moult RG, Bekerman C. Altered biodistribution of Ga-67 by intramuscular gold salts. Clin Nucl Med 1989;14:831-3.
  134. Noujaim AA, Turner CJ, Scott J. The effect of amphotericin B on 67Ga biodistribution. Int J Nucl Biol 1985;12:70-2.
  135. Bomber P, McReady R, Hammersley P. Propranolol hydrochloride enhancement of tumor perfusion and uptake of galliun-67 in a mouse sarcoma. J Nucl Med 1986;27:243-5.
  136. Brown SJ, Slizofski WJ, Dadparvar S. Altered biodistribution of gallium-67 in a patient with aluminum toxicity treated with desferoxamine. J Nucl Med 1990;31:115-7.
  137. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N, Dadachova E. Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. J Nucl Med 2004;45:500-7.
  138. Grayson RR. Factors which influence the radioactive iodine thyroidal uptake test. Am J Med 1960;28:397-415.
  139. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging 2002;29 (Suppl 2):S486-91.
  140. Summary of Product characteristics for Theracap131 TM, capsule.
  141. Yu MD, Shaw SM. Potential interference of agents on radioiodide thyroid uptake in the euthyroid rat. J Nucl Med 2003;44:832-8.
  142. Laurie AJ, Lyon SG, Lasser EC. Contrast material iodides: potential effects on radioactive iodine thyroid uptake. J Nucl Med 1992;33:237-8.
  143. Chung CJ, Hicklin OA, Payan JM, Gordon L.Indium-111-labeled leukocyte scan in detection of synthetic vascular graft infection: the effect of antibiotic treatment. J Nucl Med 1991;32:13-5.
  144. Vandenbroucke-Grauls CM, Thijssen RM, Marcelis JH, Sharma SD, Verhoef J. Effects of lysosomotropic amines on human polymorphonuclear leucocyte function. Immunology 1984;51:319-26.
  145. Challa S, Lyons KP, Broekelschen P, Milne N. Relative sensitivity of Tc-99m WBC versus In-111 WBC in a patient with Crohn disease and steroid use. Clin Nucl Med 1997;22:700-3.
  146. Sampson CB. Complications and difficulties in radiolabelling blood cells: a review. Nucl Med Commun 1996;17:648-58.
  147. Sampson CB. Interference of patient medication in the radiolabelling of white blood cells: an update. Nucl Med Commun 1998;19:529-33.
  148. Dorr U, Rath U, Sautter-Bihl ML, Guzman G, Bach D, Adrian HJ et al. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med 1993;20:431-3.
  149. Harasko-van der Meer C, Brucke T, Wenger S, Fischer P, Deecke L, Podreka I. Two cases of long term dopamine D2 receptor blockade after depot neuroleptics. J Neural Transm Gen Sect 1993;94:217-21.
  150. Frankle WG, Gil R, Hackett E, Mawlawi O, Zea-Ponce Y, Zhu Z. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. Psychopharmacology (Berl) 2004;175:473-80.
  151. Tauscher J, Kufferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl) 2002;162:42-9.
  152. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-Dopa. J Nucl Med 1996;37:1112-5.
  153. Ficha técnica de DATSCAN 74MBq/ml (solución inyectable). http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000266/WC500035355.pdf
  154. Cortés-Blanco A. Especificaciones actuales de la ficha técnica de los radiofármacos fludesoxiglucosa (18F) autorizados para comercialización en España. Seguridad Nuclear 2006;40:20-8.
  155. Blodgett TM, Ames JT, Torok FS, McCook BM. Diffuse bone marrow uptake on whole-body F-18 fluordeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med 2004;29:161-3.
  156. Mayer D, Bednarcczyk EM. Interaction of colony stimulating factors and fluordeoxyglucose F18 positron emission tomography. An Pharmacotherapy 2002;36:1796-9.
  157. Theodore WH, Bairamian D, Newmark ME, DiChiro G, Porter RJ, Larson S, Fishbein D. Effect of phenytoin on human cerebral glucose metabolism. J Cereb Blood Flow 1986;6:315-20.
  158. Roelcke U, Blasberg RG, von Ammon K, Hofer S, Vontobel P, Maguire RP. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 1998;39:879-84.
  159. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995;83:657-64.
  160. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 1996;153:41-9.